Revitope's proprietary Precision Guided Antibody Tumor Engager (PrecisionGATE) technology platform exploits coexpressed tumor antigens to enable the development of highly specific cancer drugs with improved safety and efficacy over other conventional immunotherapies. The approach combines a pair of tumor-targeted antibodies with a shared silent T-cell engaging domain that becomes active only when they encounter cancers cells that coexpress both antigens. This technology allows for a highly selective dual-antigen targeting mechanism to elicit a focused gated immune response to tumor cells

Under the terms of the collaboration, Revitope will collaborate with Janssen to conduct a feasibility study of Revitope's technology platform. The agreement was facilitated by Johnson & Johnson Innovation. Financial details of the collaboration were not disclosed.

Janssen acquires rights to AMD gene therapy
Janssen Pharmaceuticals has acquired rights of Hemera Biosciences' investigational gene therapy, HMR59, a one-time, outpatient, intravitreal injection...